Celgene (Nasdaq: CELG) shares are lower following news that the pharma has been sued over Thalidomide patent use. Bloomberg reported today that Andrulis Pharmaceuticals filed the suit against Celgene. Andrulis is seeking a ruling in …
ASTRAZENECA ENTERS STRATEGIC IMMUNO-ONCOLOGY COLLABORATION WITH CELGENE CORPORATION TO DEVELOP PD-L1 INHIBITOR PROGRAMME FOR PATIENTS WITH SERIOUS BLOOD CANCERS AstraZeneca and …